Find clinical trials

The study aims to enrol 150 people with inflammatory skin conditions such as psoriasis. The study will collect samples from volunteers. These will be used to try and understand the role of antigen presentation in people with these diseases. Specifically, the research aims to identify pathogenic peptides in lesional vs. Non lesional skin. This could lead to more personalised and effective treatments for psoriasis and ultimately improve patient care.

LY4152199 is a human BAFF-R×CD3 bispecific antibody that engages BAFF-R on the surface of B-cells and CD3 on the surface of T-cells, with the goal of T-cell-mediated elimination of BAFF-R expressing malignant B-cells. Cohort A will assess the safety, tolerability, PK, and preliminary efficacy of escalating doses of LY4152199, administered via intravenous (IV) infusion, in participants with select relapsed/refractory B-cell malignancies. Cohort B will further assess the safety, tolerability, PK, and preliminary efficacy of LY4152199 in participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).